Targeting virulence: A new paradigm for antifungals

Drug Discovery Today

Volumn 14, Issue 3-4, 2009, Pages 214-222

  Gauwerky, Katharina ^a   Borelli, Claudia ^a   Korting, Hans C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,12 BIS(TRIBUTYLPHOSPHONIUM)DODECANE DIBROMIDE; ALDEHYDE; ALEXIDINE; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; AUREOBASIDIN A; CALCINEURIN; CATALASE; CYCLOSPORIN A; ELASTASE; FUNGUS ANTIBODY; INDINAVIR; KHAFREFUNGIN; MELANIN; PEPSTATIN; PHOSPHOLIPASE; RITONAVIR; SAPONIN; SAQUINAVIR; TACROLIMUS; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; DRUG RESEARCH; DRUG TARGETING; FUNGAL VIRULENCE; HUMAN; IMMUNOCOMPROMISED PATIENT; MYCOSIS; NONHUMAN; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; OPPORTUNISTIC INFECTIONS; VIRULENCE;

EID: 58849109341     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.11.013     Document Type: Review

References (71)

1. Projan S.J., and Youngman P.J. Antimicrobials: new solutions badly needed. Curr. Opin. Microbiol. 5 (2002) 463-465
2. Alksne L.E., and Projan S.J. Bacterial virulence as a target for antimicrobial chemotherapy. Curr. Opin. Biotechnol. 11 (2000) 625-636
3. Kuhn T.H. The Structure of Scientific Revolutions (1962), University of Chicago Press, Chicago
4. Alekshun M.N., and Levy S.B. Targeting virulence to prevent infection: to kill or not to kill?. Drug Discov. Today: Therap. Strat. 1 (2004) 483-489
5. Jones B.D., and Falkow S. Salmonellosis: host immune responses and bacterial virulence determinants. Annu. Rev. Immunol. 14 (1996) 533-561
6. Falkow S. Molecular Koch's postulates applied to microbial pathogenicity. Rev. Infect. Dis. 10 (1988) S274-S276
7. Mahan M.J., et al. Selection for bacterial genes that are specifically induced in host tissues: the hunt for virulence factors. Infect. Agents Dis. 2 (1993) 263-268
8. De Saizieu A., et al. Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nat. Biotechnol. 16 (1998) 45-48
9. Ollert M.W., et al. Increased expression of Candida albicans secretory proteinase, a virulence factor, in isolates from human immunodeficiency virus-positive patients. J. Clin. Microbiol. 33 (1995) 2543-2549
10. Richardson M.D. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 56 Suppl. 1 (2005) i5-i11
11. Sheppard D.C., et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 48 (2004) 1908-1911
12. Wu T., et al. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob. Agents Chemother. 44 (2000) 1200-1208
13. Navarathna D.H., et al. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J. Antimicrob. Chemother. 56 (2005) 1156-1159
14. Hoegl L., et al. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: results of a study over a period of 2 years. Mycoses 41 (1998) 321-325
15. Korting H.C., et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob. Agents Chemother. 43 (1999) 2038-2042
16. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12 (1999) 501-517
17. Johnson E.M., et al. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35 (1995) 103-114
18. Rex J.H., et al. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39 (1995) 1-8
19. Elewski B., and Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther. Clin. Risk Manage. 1 (2005) 299-306
20. Ortonne P., et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 1307-1313
21. Haria M., and Bryson H.M. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49 (1995) 103-120
22. Francis P., and Walsh T.J. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15 (1992) 1003-1018
23. Gaughran J.P., et al. Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo. J. Bacteriol. 176 (1994) 5857-5860
24. Walsh T.J., and Giri N. Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur. J. Clin. Microbiol. Infect. Dis. 16 (1997) 93-97
25. Monod M., et al. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology 144 (1998) 2731-2737
26. Felk, A. et al. (2000) Candida albicans secretory aspartic proteinase (Sap10) gene. GenBank Accession number AF146440
27. Borelli C., et al. X-ray structures of Sap1 and Sap5: structural comparison of the secreted aspartic proteinases from Candida albicans. Proteins 72 (2008) 1308-1319
28. Cutfield S., et al. Crystallization of inhibited aspartic proteinase from Candida albicans. J. Mol. Biol. 234 (1993) 1266-1269
29. Borelli C., et al. The crystal structure of the secreted aspartic proteinase 3 from Candida albicans and its complex with pepstatin A. Proteins 68 (2007) 738-748
30. De Bernardis F., et al. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect. Immun. 63 (1995) 1887-1892
31. Hube B., et al. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol. Microbiol. 14 (1994) 87-99
32. Schaller M., et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect. Immun. 71 (2003) 3227-3234
33. Naglik J.R., et al. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect. Immun. 67 (1999) 2482-2490
34. Rüchel R., and Böning B. Detection of Candida proteinase by enzyme immunoassay and interaction of the enzyme with alpha-2-macroglobulin. Immunol. Methods 61 (1983) 107-116
35. Tsushima H., et al. Candida albicans aspartic proteinase cleaves and inactivates human epidermal cysteine proteinase inhibitor, cystatin A. Microbiology 140 (1994) 167-171
36. Tsushima H., and Mine H. Cleavage of human big endothelin-1 by Candida albicans aspartic proteinase. Immunol. Med. Microbiol. 11 (1995) 69-72
37. Albrecht A., et al. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J. Biol. Chem. 281 (2006) 688-694
38. Mirbod F., et al. Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans. Biochim. Biophys. Acta 1257 (1995) 181-188
39. Birch M., et al. Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect. Immun. 64 (1996) 751-755
40. Ghannoum M.A. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev. 12 (2000) 122-143
41. Latgé J.P. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9 (2001) 382-389
42. Paris S., et al. Catalases of Aspergillus fumigatus. Infect. Immun. 71 (2003) 3551-3562
43. Blankenship J.R., et al. Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot. Cell 2 (2003) 422-430
44. Cramer R.A., et al. Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot. Cell 7 (2008) 1085-1097
45. Wheeler M.H., and Bell A.A. Melanins and their importance in pathogenic fungi. In: McGinnis M.R. (Ed). Curr. Top. Med. Mycol. (1988), Springer, Berlin 338-387
46. Brush L., and Money N.P. Invasive hyphal growth in Wangiella dermatitidis is induced by stab inoculation and shows dependence upon melanin biosynthesis. Fungal Genet. Biol. 28 (1999) 190-200
47. Huffnagle G.B., et al. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155 (1995) 3507-3516
48. Langfelder K., et al. Biosynthesis of fungal melanins and their importance for human pathogenic fungi. Fungal Genet. Biol. 38 (2003) 143-158
49. Sugimoto Y., et al. IPC synthase as a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 4 (2004) 311-322
50. Mare L., et al. APP1 transcription is regulated by IPC1-DAG pathway and is controlled by ATF2 transcription factor in Cryptococcus neoformans. J. Biol. Chem. 280 (2005) 36055-36064
51. Heung L.J., et al. The role and mechanism of diacyglycerol-protein kinase C1 signaling in melanogenesis by Cryptococcus neoformans. J. Biol. Chem. 280 (2005) 28547-28555
52. Gerik K.J., et al. Cell wall integrity is dependent on the PKC1 signal transduction pathway in Cryptococcus neoformans. Mol. Microbiol. 58 (2005) 393-408
53. Shea J.M., and del Poeta M. Lipid signaling in pathogenic fungi. Curr. Opin. Microbiol. 9 (2006) 352-358
54. Semighini C.P., et al. Farnesol-induced apoptosis in Aspergillus nidulans reveals a possible mechanism for antagonistic interactions between fungi. Mol. Microbiol. 59 (2006) 753-764
55. Schnuch A., et al. Contact allergy to farnesol in 2021 consecutively patch tested patients. Results of the IVDK. Contact Dermatitis 50 (2004) 117-121
56. Rüchel R., et al. Modulation of experimental systemic murine candidosis by intravenous pepstatin A. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig. 273 (1990) 391-403
57. Zingman B.S. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334 (1996) 1674-1675
58. Cauda R., et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Aquir. Immune Def. Syndr. 21 (1999) 20-25
59. Ascencio M.A., et al. Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis. Chemotherapy 51 (2005) 252-255
60. Pichová I., et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur. J. Biochem. 268 (2001) 2669-2677
61. De Bernardis F., et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis. 195 (2007) 149-157
62. Abad-Zapatero C., et al. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci. 5 (1996) 640-652
63. Ganendren R., et al. In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob. Agents Chemother. 48 (2004) 1561-1569
64. Huai Q., et al. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. USA 99 (2002) 12037-12042
65. Liu J., et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
66. Takesako K., et al. Biological properties of aureobasidin A, a cyclic depsopeptide antifungal antibiotic. J. Antibiot. (Tokyo) 46 (1993) 1414-1420
67. Battinelli L., et al. In vitro antifungal and anti-elastase activity of some aliphatic aldehydes from Olea europaea L. fruit. Phytomedicine 13 (2006) 558-563
68. Zhang J.D., et al. Antifungal activities and action mechanisms of compounds from Tribulus terrestris L. J. Ethnopharmacol. 103 (2006) 76-84
69. Tang C.M., et al. Microbial genome sequencing and pathogenesis. Curr. Opin. Microbiol. 1 (1998) 12-16
70. Rosamond J., and Allsop A. Harnessing the power of the genome in the search for new antibiotics. Science 287 (2000) 1973-1976
71. Bassler B.L. How bacteria talk to each other: regulation of gene expression by quorum sensing. Curr. Opin. Microbiol. 2 (1999) 582-587